Plasma desmosine, an elastin degradation product, predicts outcomes in at risk populations

Zaid Iskandar, Ify Mordi, Jeffrey T. J. Huang, David Newby, James Chalmers, Matt Bown, Chim Lang, Anna Maria Choy

Research output: Contribution to journalArticlepeer-review


Background: Recent evidence suggest that elastin fragmentation plays a key role in plaque destabilization and rupture. Plasma desmosine is an elastin specific degradation product. We have reviewed the predictive value of plasma desmosine for outcome in a cohort of patient with cardiovascular disease and in 2 cohorts of patients with pulmonary disease who are at risk of cardiovascular events.

Methods: The results from 3 independent cohorts of patients: Magnetic resonance imaging (MRI) for abdominal aortic aneurysms to predict rupture or surgery (MA3RS trial, NCT01749280); evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE study, NCT00292552) and the Tayside Bronchiectasis Registry (TAYBRIDGE) were reviewed. The desmosine analyses were carried out in the same laboratory. Patients were followed up for clinical outcomes including all-cause mortality.

Results: Plasma desmosine was strongly related to cardiovascular disease in MA3RS and ECLIPSE and is a predictor of all-cause mortality in all 3 groups (Table 1).

Conclusion: Elevated circulating pDES is associated with increased all-cause mortality independent of underlying disease process and may be a useful universal prognostic biomarker in at risk populations.
Original languageEnglish
Pages (from-to)1805
Number of pages1
JournalJournal of the American College of Cardiology
Issue number9, Supplement 1
Early online date4 Mar 2019
Publication statusPublished - 12 Mar 2019


Dive into the research topics of 'Plasma desmosine, an elastin degradation product, predicts outcomes in at risk populations'. Together they form a unique fingerprint.

Cite this